Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-cash Items: 2014-2021

Historic Non-cash Items for ImmunityBio (IBRX) over the last 5 years, with Jun 2021 value amounting to $19.0 million.

  • ImmunityBio's Non-cash Items fell 37.37% to $19.0 million in Q2 2021 from the same period last year, while for Jun 2021 it was $19.0 million, marking a year-over-year decrease of 37.37%. This contributed to the annual value of $21.9 million for FY2020, which is 283.92% up from last year.
  • Per ImmunityBio's latest filing, its Non-cash Items stood at $19.0 million for Q2 2021, which was down 64.97% from $54.3 million recorded in Q1 2021.
  • Over the past 5 years, ImmunityBio's Non-cash Items peaked at $54.3 million during Q1 2021, and registered a low of $563,000 during Q4 2018.
  • For the 3-year period, ImmunityBio's Non-cash Items averaged around $14.8 million, with its median value being $7.5 million (2019).
  • Its Non-cash Items has fluctuated over the past 5 years, first slumped by 95.28% in 2018, then soared by 2,234.92% in 2020.
  • Over the past 5 years, ImmunityBio's Non-cash Items (Quarterly) stood at $11.9 million in 2017, then crashed by 95.28% to $563,000 in 2018, then spiked by 914.21% to $5.7 million in 2019, then spiked by 283.92% to $21.9 million in 2020, then slumped by 37.37% to $19.0 million in 2021.
  • Its last three reported values are $19.0 million in Q2 2021, $54.3 million for Q1 2021, and $21.9 million during Q4 2020.